Company Profiles

driven by the PitchBook Platform

Axelar

Description

Developer of anti-cancer treatments designed to target the area where there are significant unmet medical needs. The company's anti-cancer treatments focus on inhibitors of the insulin-like growth factor-1 (IGF-1) receptor and their applications in cancer, enabling patients to avail the cancer treatment at an affordable price.

2003

Founded

PRIVATE

Status

1-10

Employees

2ndary - Private

Latest Deal Type

$19.7M

Total Amount Raised

3

Investors

Description

Developer of anti-cancer treatments designed to target the area where there are significant unmet medical needs. The company's anti-cancer treatments focus on inhibitors of the insulin-like growth factor-1 (IGF-1) receptor and their applications in cancer, enabling patients to avail the cancer treatment at an affordable price.

Website:

www.axelar.se

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

Karolinska Institutet Science Park Fogdevreten 2 171 65 SolnaSweden +46 (0)8 446 835 81
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Axelar's full profile, request a free trial.

    Axelar Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Axelar Investors (3)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    btov PartnersVenture CapitalMinority000 0000000 0000
    ÖstersjöstiftelsenOtherMinority000 0000000 0000
    Rosetta Capital(London)Venture CapitalMinority000 0000000 0000
    btov Partners Venture Capital
    Östersjöstiftelsen Other
    Rosetta Capital(London) Venture Capital

    Axelar Executive Team (8)

    NameTitleBoard
    Seat
    Contact
    Info
    Lars Abrahmsén Ph.DVice President, Preclinical Development & Chief Scientific Officer
    Maria KlockareDirector, Clinical Operations
    Ninus Caram-Lelham Ph.DDirector CMC, Drug Substance
    Ann-Sofie SternåsDirector, Intellectual Property
    Kristina CarlsonDirector, Regulatory Affairs
    Lars Abrahmsén Ph.D Vice President, Preclinical Development & Chief Scientific Officer
    Maria Klockare Director, Clinical Operations
    Ninus Caram-Lelham Ph.D Director CMC, Drug Substance
    Ann-Sofie Sternås Director, Intellectual Property
    Kristina Carlson Director, Regulatory Affairs

    Axelar Board Members (7)

    NameRepresentingRoleSinceContact
    Info
    Fredrik Gilstring MDAxelarBoard Member000 0000
    Goran PetterssonSelfBoard Member000 0000
    Jonas Ekblom Ph.DSelfChairman & Business Advisor000 0000
    Jonathan Hepple Ph.DRosetta Capital(London)Partner000 0000
    Magnus AxelsonAxelarBoard Member & Co-Founder000 0000
    Fredrik Gilstring MD Board Member Axelar
    Goran Pettersson Board Member Self
    Jonas Ekblom Ph.D Chairman & Business Advisor Self
    Jonathan Hepple Ph.D Partner Rosetta Capital(London)
    Magnus Axelson Board Member & Co-Founder Axelar
    Request full access to PitchBook